Society for Translational Oncology navigateright Episode
Massachusetts General Hospital
Extracellular vesicles have not seen widespread clinical testing due to limitations in isolation technologies that suffer from low throughput or lack of tumor-specificity. To address this, we have developed a microfluidic platform, the EVHB-Chip, for tumor-specific recovery of EVs using immunoaffinity capture. Through this blood-on-a-chip assay, we aim to gain a better understanding of when these important tumor derived vesicles are released and how we can exploit their molecular content to better guide patient treatment.
These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.